FONT-SIZE Plus   Neg

FDA Clears Gen-Probe's PANTHER System For Use With APTIMA Combo 2 Assay

Gen-Probe Inc. (GPRO) Tuesday said the US Food and Drug Administration has cleared its PANTHER system, a fully automated and integrated molecular testing platform designed with the flexibility to handle a wide range of testing needs.

The PANTHER system can initially be used to test for the common sexually transmitted infections Chlamydia trachomatis and Neisseria gonorrhoeae with the APTIMA Combo 2 assay.

According to the company, using this system, a single operator can process 275 samples in eight hours.

Gen-Probe will begin shipments of PANTHER systems to US customers during the second quarter.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Xerox (XRX) reported third-quarter adjusted earnings of $286 million or $0.27 per share compared to $289 million or $0.27 per share, last year. On average, 12 analysts polled by Thomson Reuters expected the company to report profit per share of $0.27 for the quarter. Analysts' estimates typically exclude... Baker Hughes Inc.'s shares gained around 7 percent in the extended trading on Thursday after conglomerate General Electric Co. confirmed, while responding to media reports, that it is in talks to buy the oilfield services provider. The stock is moving 6 percent ahead in the pre-market activity. Shares of Sanofi were gaining around 7 percent in the morning trading in Paris after the French drug maker on Friday raised its 2016 business earnings guidance, after it reported strong third-quarter results. In addition, the company set a 3.5 billion euros share repurchase program to be completed by the end of 2017.
comments powered by Disqus
Trade GPRO now with 
Follow RTT